Ongoing advances in the perioperative management of bladder cancer
At the 2022 NY GU Cancers Symposium, Jean Hoffman-Censits, MD, discussed the latest developments in the neoadjuvant and adjuvant setting for patients with bladder cancer.
At the 2022 NY GU Cancers Symposium, Jean Hoffman-Censits, MD, discussed the latest developments in the neoadjuvant and adjuvant setting for patients with bladder cancer.
“This data emphasizes the importance of utilizing the EPI test for risk assessment of high-risk prostate cancer in [African American] men,” concluded the authors.
Results of an exclusive Urology Times survey reveal that more than 70% of respondents said they consider age a relevant factor in the performance of…
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Sarah P. Psutka, MD, MSc, shares the rationale for the “Get Moving Trial,” exploring at-home prehabilitation for patients with muscle-invasive bladder cancer.
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to…